03.19 (È) 12:21
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
µ¶ÀÚÁ¦º¸
񃯇
񃯇
ÀǾàÇ°
³¹¾Ë½Äº°
µ¥Àϸ®ÆÊ Live Search
´Ý±â
´º½º
Àüü±â»ç
Á¤Ã¥ · ¹ý·ü
Á¦¾à · ¹ÙÀÌ¿À
¾à±¹ · º´¿ø
Ä«µå´º½º
ÆÊTV
À̽´¿µ»ó
ºÎÀۿ븮Æ÷Æ®
1µî ¾à±¹À» ã¾Æ¼
½ºÆ¿ÄÆ ¿µ»ó
¿ÀÇǴϾð
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
±âÀÚÀÇ ´«
µ¶ÀÚ±â°í
English
Policy
Opinion
Company
Product
Interview
TVÆʵµ¶ó
ÆÊTube
ÆʼîÇÎ
³ª´Â¾à»ç´Ù
Æʵå¶ó¸¶
ÆʾÆÄ«µ¥¹Ì
Á¦Ç°°ÁÂ
Çмú°ÁÂ
°æ¿µ°ÁÂ
Ä¿¹Â´ÏƼ
Æʸ®Äí¸£Æ®
ä¿ëÁ¤º¸
PHARMARCY
ÀÎÀçÁ¤º¸
DPºÎµ¿»ê
¾à±¹»ó´ã¼Ò
¾à±¹´ëÃâ
¼¼¹«»ó´ã
¹ý·ü»ó´ã
¾à±¹ÈÀåÇ°
¾à±¹°æ¿µ
¾à»ç´ëÃâ
ÀǾàÀÚ·á½Ç
ÀǾàÇàÁ¤
¾à»ç¾à±¹
ÀǷẴ¿ø
Á¦¾àÀ¯Åë
º¸µµÀÚ·á
ÆÊÆ÷ÀÎÆ®¸ô
À¯¸Ó · ¸¸È
ÀÎ»ç · ºÎÀ½
¾à±¹ÀåÅÍ
ȸ»ç¼Ò°³
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
»ç¾÷Á¦ÈÞ
ÀÎÅͳݽŹ®À±¸®°·É
µ¶ÀÚÁ¦º¸
±âÀÚÀ±¸®°·É
ÀÚÀ²¼¾à¼
¿ø°ÝÁö¿ø¿äû
Event & ¼¼¹Ì³ª
´º½º
English
ÆÊTV
¿ÀÇǴϾð
Æʸ®Äí¸£Æ®
DPºÎµ¿»ê
TVÆʵµ¶ó
ÆÊÆ÷ÀÎÆ®¸ô
ÆʾÆÄ«µ¥¹Ì
Event
Åڹ̻縣ź ù ¼±µÎ...¹ß»ç¡¤·Î»ç¸£Åº, ºÒ¼ø¹° ¸í¿¹È¸º¹
ºÒ¼ø¹° ±¸°æµµ ¸øÇߴµ¥...¼öŹ»ç ´«Ä¡º¸´Â Á¦¾à»çµé
'ºÒ¼ø¹° À̽´' ¹Ì¶óº£±×·Ð ½ÃÀå 20%¡è...Á¦³×¸¯ ¾àÁø
'ÃÑ »ó±Ý 1¾ï¿ø'...2024 Àü±¹ ¾à»ç¡¤ºÐȸ ÀÚ¶û ÄÜÅ×½ºÆ® °ø¸ð
ºÐȸ ȸ¹«ºÎ¹® ´ë»ó 2õ¸¸¿ø µî...4¿ù1ÀÏ~5¿ù10ÀϱîÁö Á¢¼ö
ȸ¹«¡¤Àå±âÀÚ¶û¡¤°£ÆDZîÁö...ºÐȸ ÄÜÅ×½ºÆ® ¿µ±¤ÀÇ ¾ó±¼µé
Áö±Ý µ¥Àϸ®ÆÊ¿¡¼± ¾à»çºÐȸ ÀÚ¶û ÄÜÅ×½ºÆ® ÅõÇ¥ ÁøÇàÁß
Á¦1ȸ Àü±¹ ¾à»çºÐȸ ÀÚ¶û ÄÜÅ×½ºÆ® ¿¸°´Ù...ÃÑ»ó±Ý 1¾ï
¿©´ç, ºñ´ë¸é ¾à ¹è¼Û¡¤ºñ¸¸Ä¡·áÁ¦ ±Þ¿© ÃßÁø...ÃѼ± °ø¾à
°£¾Ï 2Â÷ '½ºÆ¼¹Ù°¡' À§ÇèºÐ´ãÁ¦ µÎ¹ø° Àç°è¾à ÇÕÀÇ
ÀÌÁßÇ×ü¡¤ADC ¼º°ú ¼Ò°³¡¦K-¹ÙÀÌ¿À, R&D °æÀï·Â ½ÃÇè´ë
Æĸ¶¸®¼Ä¡ SD¿Í ¼ÕÀ⳪¡¦¾¾Æ¼¾¾¹ÙÀÌ¿À ºÐÀï »õ ±¹¸é
±¹°¡ÇʼöÀǾàÇ° 4°³ ±×·ìÀ¸·Î ±¸ºÐ...Á¤±âÀû µî±Þ °ü¸®
SELECT COUNT(*) FROM Poll_Vote WHERE Poll_ID='206' AND Example_ID='407' AND Poll_Vote.voteType ='V'
SELECT COUNT(*) FROM Poll_Vote WHERE Poll_ID='206' AND Example_ID='408' AND Poll_Vote.voteType ='V'
Issue & Poll
ÀÇ´ë 2õ¸í Áõ¿ø±Ô¸ð Ãà¼ÒÁ¶Á¤?
Ãà¼ÒÇؾß
VS.
¿ø¾È À¯ÁöÇؾß
ÅõÇ¥ & ÀÇ°ß¾²±â
DPÃÊ´ë¼®
[DPÃÊ´ë¼®] ÀåÁöÈñ °Çº¸°ø´Ü ÀÇ·áÀÌ¿ëÁö¿øºÎÀå
´«¿¡ ¶ç´Â CF
µ¿±¹Á¦¾à-Ä«¸®ÅäÆ÷ÅÙ
Á¦ÀÏÇコ»çÀ̾ð½º-Á¦ÀÏÆÄÇÁ
ÆÊTV
ÇؿܾడÀçÆò°¡, ÀïÁ¡°ú Á¦¾à»ê¾÷°è ¹Ý¹ß ÀÌÀ¯´Â?
ÆÊTalk
"ÄÚ¸·Èû ¹Û¿¡ ¾ø´Ù°í?"...½´µµ¿¡Æäµå¸°ÀÇ ÀÀ¿ë
¿À´ÃÀÇ
ÇÖ´º½º
1
¿©´ç, ºñ´ë¸é ¾à ¹è¼Û¡¤ºñ¸¸Ä¡·áÁ¦ ±Þ¿© ÃßÁø...ÃѼ± °ø¾à
2
ÀÇ»ç 4¸í ºñ·Ê´ëÇ¥ ´ç¼±±Ç...¾à»ç¡¤ÇÑÀǻ硤°£È£»ç °íÀü
3
"4³â Àü°ú ´Ù¸£´Ù"...°³¿øÀÇ Æľ÷ Âü¿© °¡´É¼ºÀº?
4
Åڹ̻縣ź ù ¼±µÎ...¹ß»ç¡¤·Î»ç¸£Åº, ºÒ¼ø¹° ¸í¿¹È¸º¹
5
Æĸ¶¸®¼Ä¡ SD¿Í ¼ÕÀ⳪¡¦¾¾Æ¼¾¾¹ÙÀÌ¿À ºÐÀï »õ ±¹¸é
6
ÀÌÁßÇ×ü¡¤ADC ¼º°ú ¼Ò°³¡¦K-¹ÙÀÌ¿À, R&D °æÀï·Â ½ÃÇè´ë
7
'ÃÑ »ó±Ý 1¾ï¿ø'...2024 Àü±¹ ¾à»ç¡¤ºÐȸ ÀÚ¶û ÄÜÅ×½ºÆ® °ø¸ð
8
±¹°¡ÇʼöÀǾàÇ° 4°³ ±×·ìÀ¸·Î ±¸ºÐ...Á¤±âÀû µî±Þ °ü¸®
9
°£¾Ï 2Â÷ '½ºÆ¼¹Ù°¡' À§ÇèºÐ´ãÁ¦ µÎ¹ø° Àç°è¾à ÇÕÀÇ
10
°æ¹æ½Å¾à, ¸ÅÃâ 556¾ï ´Þ¼º..."CMO »ç¾÷ ½ÂºÎ¼ö"
"4³â Àü°ú ´Ù¸£´Ù"...°³¿øÀÇ Æľ÷ Âü¿© °¡´É¼ºÀº?
°³¿øÀÇÇùÀÇȸ Áý´ÜÇൿ Á¶Áü¿¡µµ µ¿Âü ÀúÁ¶ ¿¹»ó
"ÀÇ´ë±³¼öµµ »çÁ÷ÇÑ´Ù±¸¿ä?"¡¦¹®Àü¾à±¹ °¡½Ã¹ç±æ
ÀÇ¿ø±Þ ºñ´ë¸é 4¸í Áß 1¸í °¨±â...¾à±¹ Á¦ÈÞ 3¹è ±ÞÁõ
"ó¹æ 20% ÁÙ¾ú´Ù"...Àü°øÀÇ ÀÌÅ»¿¡ ¹®Àü¾à±¹ »ì¾óÀ½ÆÇ
À±, ÀÇ´ë 2õ¸í °í¼ö¡¦"Áö¿ªÀÇ´ëºÎÅÍ ¹èÁ¤ÇÏ°í ƯÀ§ °¡µ¿"
°æ¹æ½Å¾à, ¸ÅÃâ 556¾ï ´Þ¼º..."CMO »ç¾÷ ½ÂºÎ¼ö"
¾Æ»êº´¿ø ãÀº À± ´ëÅë·É, ´Ü°èÀû ÀÇ´ë Áõ¿ø³íÀÇ ÀÏÃà
¿©´ç ºñ·Ê´ëÇ¥, ¾à»ç Àü¿ø Å»¶ô¡¦ÀÇ»ç 2¸í ´ç¼±±Ç
"°íÀÛ ¾à±¹ 12°÷?"...¾à»çȸ ¼ÒºÐ°Ç±â½Ä ¾îµð±îÁö ¿Ô³ª
ÀÇ»ç 4¸í ºñ·Ê´ëÇ¥ ´ç¼±±Ç...¾à»ç¡¤ÇÑÀǻ硤°£È£»ç °íÀü
¹ÎÁÖ´ç ÀÌ¾î ±¹Èû¼µµ ºñ·Ê´ëÇ¥ ¾à»ç Àü¸ê
¿©´ç ºñ·Ê´ëÇ¥, ¾à»ç Àü¿ø Å»¶ô¡¦ÀÇ»ç 2¸í ´ç¼±±Ç
ÃѼ± ¾à»çÃâ½Å Áö¿ª±¸ Èĺ¸ È®Á¤...±¹Èû 0¸í, ¹ÎÁÖ 4¸í
¹ÎÁÖ´ç ºñ·Ê´ëÇ¥ È®Á¤...ÀǾà»ç µî º¸°ÇÀÇ·áÀÎ Àü¹«
ÄÚǪÁ¤ µî 4Ç°¸ñ¡¤Çϸð´Ò¶õ¡¤Å©·¡¹ÖÁ¤ ³»´Þ ¾à°¡Àλó
Àü°øÀÇ Æľ÷ ¿©ÆÄ¿¡ »õ³»±â ¾à»ç ±¸Àα¸Á÷µµ Âù¹Ù¶÷
'6959¾ï¡æ1582¾ï'...SK¹Ù»ç, ³»¼ö ¸ÅÃâ ¿£µ¥¹Í ÈÄÀ¯Áõ
¸¶¾à·ù °ü¸® ¼ÒȦ ´ëÇк´¿ø¡¤¹ÙÀÌ¿Àº¥Ã³ µî ¾÷¹«Á¤Áö
"¼Òû°ú¡¤»êºÎÀΰú¿¡ 3Á¶ ÅõÀÔ¡¦ÇàÀ§º°¼ö°¡Á¦ Çõ½Å ½Ãµ¿"
»óÀåÁ¦¾à Àý¹Ý ¿µ¾÷ÀÍ¡é...´ëÇü¡¤Áß¼Ò ½ÇÀû ¾ç±ØÈ ½ÉÈ
TV
´ÙÁ¦¾à¹° »ç¾÷À¸·Î ó¹æÁ¶Á¤±îÁö¡¦ÀÇ¡¤¾à»ç Çù¾÷ Áß¿ä
'»ç³»À̻硤½ÂÁø' Á¦¾à»ç ¿À³Ê 2~3¼¼ °æ¿µº¸Æø È®´ë
ÃѼ± ¾à»çÃâ½Å Áö¿ª±¸ Èĺ¸ È®Á¤...±¹Èû 0¸í, ¹ÎÁÖ 4¸í
È»óÅõ¾à±â¿¡ °ø°ø½É¾ß¾à±¹±îÁö...ÇѾà»çÀÇ ¿ª½À
±¹¹Îû¿ø Ç×¾ÏÁ¦ '¿£ÇãÅõ' ¾à°¡Çù»ó ÃÊ°í¼Ó Ÿ°á
Àü°øÀÇ¡æ±³¼ö Àü¼±³ÐÈù ÀÇ·á°è¡¦Ä¡Å²°ÔÀÓ µÈ ÀÇÁ¤°¥µî
'ÈÇÕ¡¤´ÜÇÕ°ú ÀÎÀç µî¿ë'...¹ÚÈ£¿µ À¯ÅëÇùȸÀåÀÇ Æ÷ºÎ
"ÀÇ´ë±³¼öµµ »çÁ÷ÇÑ´Ù±¸¿ä?"¡¦¹®Àü¾à±¹ °¡½Ã¹ç±æ
"ÇöÀå¼ ¾òÀº ÀλçÀÌÆ®·Î ÃÖ°í ¾à±¹ ¿¬±¸ÀÚ µÉ°Ô¿ä"
¾à»ç Ãâ½Å ¼¿µ¼®, ¹ÎÁÖ´ç ºÎõ°© º»¼± Ã⸶ È®Á¤
±èÀ± ¼¿ïÀÇ´ë ±³¼ö, ±¹È¸ ÀÔ¼º ÆĶõºÒ...ºñ·Ê 12¹ø ¹Þ¾Æ
FDA, ù MASH Ä¡·áÁ¦ Çã°¡¡¦±Û·Î¹úÁ¦¾à °³¹ß ¼Óµµ
'±¸Á¶Á¶Á¤+ºÐ»ç' Àϵ¿, ÀÛ³â Á÷¿ø¼ö '¶Ò'...ÅðÁ÷±Ý 84%¡è
Á¦ÁÖµµ ÇѾà»ç, °ø°ø½É¾ß¾à±¹ ½Åû...¾à»çµé '¹ßĬ'
¼ÒƽÅõ¡¤¾ÆÆ®¶öÀÚ °Çº¸µîÀç ÃÊÀб⡦¼Ö¸®¸®½º ±Þ¿© È®´ë
ÀÌÁÖÇü CMGÁ¦¾à ´ëÇ¥ÀÌ»ç 4¿¬ÀÓ¡¦Àå¼ö CEO µî±Ø
"º½ÀÌ ¿Ô³ªº½" º½Ã¶ ¾à±¹ È¿ÀÚÇ°¸ñ°ú Áø¿ ÆÁÀº?
³»³âºÎÅÍ Æ¯·Ê ¹ÌÀû¿ë ¾à»çµµ 'Àü¹®¾à»ç' ÀÀ½Ã °¡´É
À¯Æ©¹ö '¾à½Î°³ÇåÅÍ' °í¹ß °æ°í ÇϷ縸¿¡ ä³Î »èÁ¦
MSD SGLT2 ¾ïÁ¦Á¦, ÁÙÁÙÀÌ Ã¶¼ö...½ºÅ×±Û·çÀÜ °ø±Þ Áß´Ü
½Ã½Å°æô¼ö¿° ½Å¾à '¿£½ºÇÁ¸µ' Á¾ÇÕº´¿ø ó¹æ±Ç ÁøÀÔ
"Àü°øÀÇ ÀÇ·á°ø¹é, ÀÇ·áÀü´Þü°è Á¤»óÈ °è±â·Î Àû±Ø È°¿ë"
"2Â÷º´¿ø ÆÐ½Ì ÇؼÒÇÏ°í Á¾º° ±â´É »ì¸° Àü´Þü°è ÇÊ¿ä"
[CSL Behring] Sales Lead ¶Ç´Â MR
[Sanofi/»ç³ëÇÇ] RA Specialist
Medical Operations Coordinator (°è¾àÁ÷)
°¢ ºÎ¹® ±¸¼º¿ø ¿µÀÔ
[ºñŸ¹ÎÇϿ콺] ¾à»ç °æ·ÂÁ÷ ä¿ë
Medical ¹× Clinical °¢ ºÎ¹® ä¿ë
Regulatory Affairs Specialist
¼Ûµµ/¿À¼Û/ºÎ»ê Á¦Á¶/Ç°Áú°ü¸® ¾à»ç ¸ðÁý
Medical Lead - CML
[CSL Behring] (Junior) Product Manager
CVT MSL(Medical Scientific Liaison) Á¤±ÔÁ÷
Sr. RA Specialist, RA Speaiclist ä¿ë
Medical Communication & Strategy
ÀÌ·ÊÀûÀÎ '¿£ÇãÅõ' ±Þ¿©¿Í ½Å¾à ÀÌÁ¤Ç¥
±âÀÚÀÇ ´«
¾îÀ±È£
+
¸®º£ÀÌÆ®·Î ½×¾Æ ¿Ã¸° ±ÝÀÚž
µ¥½ºÅ©½Ã¼±
³ëº´Ã¶
+
ÀϺΠŸÀÌ·¹³î Ç°¸ñ, »ý»êÁß´Ü 2³â° »óºñ¾à ¸ñ·Ï¿¡
±âÀÚÀÇ ´«
ÀÌÇý°æ
+
µ¿¾Æ½î½Ã¿À¿Í ¿¹Ãø°¡´É¼ºÀÇ Èû
±âÀÚÀÇ ´«
À̼®ÁØ
+
µ¿Á¤
ÀÌ°´ë °í½Å´ëº´¿ø ±³¼ö, ¹ü»êÇмú»ó ¼ö»ó
µ¿Á¤
¾ç½Â´ö Àü ûÁÖ½ÃÀÇ»çȸÀå, ÃæºÏÀÇ»çȸÀå ¼±Ãâ
ºÎÀ½
¼È«¹Î ½Å¶óÁ¨-¿¥Åõ¿£ ȸÀå ºÎÄ£
ºÎÀ½
ÀÌÁø¼® È޿½º±Û·Î¹ú ±âȹÁ¶Á¤º»ºÎÀå ¸ðÄ£
ÀÎÅͺä
"ÇöÀå¼ ¾òÀº ÀλçÀÌÆ®·Î ÃÖ°í ¾à±¹ ¿¬±¸ÀÚ µÉ°Ô¿ä"
°èÈñ¿¬ ¾à»ç(¹Ú»ç)
¿À´ÃÀÇ ´Ü½Å
Àüü
|
Á¤Ã¥°ú ¹ý·ü
|
Á¦¾à¡¤¹ÙÀÌ¿À
|
º´¿ø¡¤¾à±¹
ÀÓÇöÅà ¼Òû°úÀÇ»çȸÀå, º¹ÁöºÎ À塤Â÷°ü °ø¼öó °í¹ß
´ë¿õÁ¦¾à "¿£ºí·Î, ½ÅÀåÁúȯ ´ç´¢º´¼ °æÀï¾àº¸´Ù È¿°ú"
ÆÄÁÖ¿¡ 2È£ ´Þºû¾î¸°À̺´¿ø ÁöÁ¤...Çù·Â¾à±¹µµ ¿î¿µ
°Ç¾à "Ç°Àý¾à, ±¹°¡Ã¥ÀÓÁ¦°¡ ´ä"¡¦Á¤´ç¿¡ ¿ä±¸¾È Àü´Þ
¸ù°ñ ¿Ü°úÀÇ»ç ½Â±Þ½ÃÇè ¿ä°Ç¿¡ ÁøÈï¿ø ¿¬¼ö ÁöÁ¤
¸ù°ñ ¿Ü°úÀÇ»ç ½Â±Þ½ÃÇè ¿ä°Ç¿¡ ÁøÈï¿ø ¿¬¼ö ÁöÁ¤
±è¼±¹Î Àü ½ÉÆò¿øÀå, Á¶±¹Çõ½Å´ç ºñ·Ê 5¹ø ¹èÁ¤
"ÀÇ´ë±³¼ö »çÁ÷ ½Ã ¿øÄ¢ ´ëÀÀ¡¦2õ¸í ±Ô¸ð ³íÀÇ ¿·ÁÀÖ´Ù"
½Ä¾àó, ÀνºÅ¸ µî °Ç±â½Ä ºÎ´ç±¤°í °èÁ¤ ¿î¿µÀÚ Àû¹ß
µ¿±¹Á¦¾à, '¶óº£µå' Á¦Á¶Á¤Áö ´ë½Å °ú¡±Ý 4230¸¸¿ø óºÐ
´ë¿õÁ¦¾à "¿£ºí·Î, ½ÅÀåÁúȯ ´ç´¢º´¼ °æÀï¾àº¸´Ù È¿°ú"
¼¿Æ®¸®¿Â, ¹Ì±¹¼ 'ÁüÆæÆ®¶ó' ¹ß¸Å...ù ½Å¾à Ãâ°Ý
¼¿·¦¸Þµå, ¹Ì±¹¾Ï¿¬±¸ÇÐȸ¼ »õ·Î¿î CAR-T Àü·« °ø°³
¼¿¸Þµå, ȨÆäÀÌÁö »õ´ÜÀ塦"¾à±¹ °í°´¿¡ ºê·£µå °¡Ä¡ Àü´Þ"
À¯Ã¢ÈÆ ¾Æ»êº´¿ø ±³¼ö, °£¾ÏȯÀÚ¼ ƯÁ¤´Ü¹éÁú ¹ßÇö ¹ß°ß
ÀÓÇöÅà ¼Òû°úÀÇ»çȸÀå, º¹ÁöºÎ À塤Â÷°ü °ø¼öó °í¹ß
ÆÄÁÖ¿¡ 2È£ ´Þºû¾î¸°À̺´¿ø ÁöÁ¤...Çù·Â¾à±¹µµ ¿î¿µ
°Ç¾à "Ç°Àý¾à, ±¹°¡Ã¥ÀÓÁ¦°¡ ´ä"¡¦Á¤´ç¿¡ ¿ä±¸¾È Àü´Þ
°æ±â ºÎõ°© Ã⸶ ¼¿µ¼® ÀÇ¿ø "½Â¸®ÇØ ¹Î»ý ȸº¹½Ãų °Í"
º´¿ø¾à»çȸ ¿ª´ë ȸÀå´Ü ¸ð¿© 40³â»ç ¹ß°£ ÃàÇÏ
±è¼±¹Î Àü ½ÉÆò¿øÀå, Á¶±¹Çõ½Å´ç ºñ·Ê 5¹ø ¹èÁ¤
°æ±â ºÎõ°© Ã⸶ ¼¿µ¼® ÀÇ¿ø "½Â¸®ÇØ ¹Î»ý ȸº¹½Ãų °Í"
º´¿ø¾à»çȸ ¿ª´ë ȸÀå´Ü ¸ð¿© 40³â»ç ¹ß°£ ÃàÇÏ
"ÀÇ´ë±³¼ö »çÁ÷ ½Ã ¿øÄ¢ ´ëÀÀ¡¦2õ¸í ±Ô¸ð ³íÀÇ ¿·ÁÀÖ´Ù"
¼¿Æ®¸®¿Â, ¹Ì±¹¼ 'ÁüÆæÆ®¶ó' ¹ß¸Å...ù ½Å¾à Ãâ°Ý
´Ý±â
½Ä¾àó, 15ÀÏ ¸¶¾à·ù ÀÇ·á¼îÇÎ ¹æÁö Á¤º¸¸Á °íµµÈ ¼³¸íȸ
½Ä¾àó, ¹Î°ü¼ÒÅëÇùÀÇü 'ÆÊÅõ°Ô´õ' Çùȸ Âü¼® Ƚ¼ö È®´ë
ÇѸ¶À½Ç÷¾×¿ø-Çѱ¹³ëÃÑ »êÇÏ´Üüµé°ú ÇåÇ÷ ³ª´®Çù¾à
¾à±¹¿¡¼ ±¸¸ÅÇØ¾ß Çϴµ¥...Å»¸ð¾à °³Àΰŷ¡ Àû¹ß
±è»óÈñ, ºÎõº´ °æ¼± Å»¶ô¡¦¼¿µ¼®, ºÎõ°© °á¼± ÁøÃâ
´Ý±â
Æĸ¶¸®¼Ä¡ '¸®Áê¶õ¢ç' µÎ¹ÙÀÌ´õ¸¶ 2024 Âü°¡
°æµ¿Á¦¾à 'ÅëÁõÀ» ´ëÇÏ´Â À¯Çüº° ¹ÝÀÀ' TV±¤°í ¿Â¿¡¾î
À¯ÇѾçÇà, Àª·Î°Ö ´õºí¾×¼Ç ´ë¿ë·® Æ÷Àå´ÜÀ§ Ãâ½Ã
Áö¿À¿µ "Áö¸£ÅØ ¸ÅÃâ ¼øÇ×...Àü³â´ëºñ 19%¡è"
ºñ¾Ø¾¾¸ÞµðÄ®, ³»½Ã°æÇÐȸ¼ 'ÆÄÀÌ·ÎÇ÷¯½º' È«º¸
´Ý±â
ÁÖ¿µ¼ö NMC¿øÀåÀÇ °á±â..."±³¼öµé ´ÜüÇൿ Âü´ã"
ÀÎõ¸¶Å𺻺Î, ½Å±Ô ¿¹¹æ°»ç ´ë»ó ¿ª·®°È ±³À° ½Ç½Ã
¼¼Á¾½Ã, ÆóÀǾàÇ° ÁýÁß¼ö°ÅÀÇ ³¯ ÅëÇØ ¹èÃâ¹ý µî ¼Ò°³
16°³ ½ÃµµÁöºÎÀå "Á¤ºÎ, ÀǾàÇ° Ç°Àý»çÅ ÇØ°áÇ϶ó"
"ÇÑ¹æ °øºÎÇÏÀÚ" À§µåÆÊ, ÇÑdzÁ¦¾à°ú ¸Å¿ù Çмú±³À°
´Ý±â
¾Ë¸² ¡¤ °øÇ¥
±³À° ¡¤ °ÁÂ
¾à±¹»ó´ã¼Ò
Á¢¼ö ¡¤ ¹®ÀÇ
¾Ë¸²
¿À¸®Áö³Î ¾Ë·¹±×¶óÀÇ Â÷ÀÌ! ¹Ù·Î°¡±â¢º
¾Ë¸²
Á¦ 8ȸ ´ÚÅ;ØÆÊ °³±¹ ¼¼¹Ì³ª 3¿ù 24ÀÏ(ÀÏ) GO¢º
°øÁö
º¸·É °ÖÆ÷½º¿¥ ¸®´º¾ó À̺¥Æ® ´ç÷ÀÚ!
¾Ë¸²
[3RÄÚ¸®¾Æ]ICT ±ÔÁ¦»÷µå¹Ú½º ½ÇÁõ Ư·Ê ½ÂÀÎ!! ¼³Ä¡ ¹× ...
¾Ë¸²
ºê·¹ÀÎÅͺä! ³ú¸¦ À§ÇÑ ÃÖÀûÀÇ Á¶ÇÕ ºê·¹ÀÌ´× GO¢º
¾Ë¸²
[ºÒ±³°øºÎ]ºñ´ë¸é ȸ¿ø ¸ðÁý GO¢º
¾Ë¸²
µðÁöÅбâ±âÀÇ °Ç°À§Çù¿£? ¾×Ƽ³Ñ! GO¢º
¾Ë¸²
MZ¾à´ë»ý ÃëÇâÀú°Ý! ŸÀÌ·¹³î»ê ¾ð¹Ú½Ì GO¢º
D-287
[ÆÊŬ·¡½º]Àü°Á ¹«Á¦ÇÑ ½Ãû! (Ç×½ÃÁ¢¼ö) ( ~12.31 )
D-287
[ÆʽºÅ͵ð]ij³ª´Ù ¾à»ç ÀÚ°ÝÁõ[Ç×½ÃÁ¢¼ö] ( ~12.31 )
D-287
[ºÒ±³°øºÎ] ºñ´ë¸é ȸ¿ø ¸ðÁý GO¢º ( ~12.31 )
D-287
Á¦ 8ȸ ´ÚÅ;ØÆÊ °³±¹ ¼¼¹Ì³ª 3¿ù 24ÀÏ(ÀÏ) GO¢º ( ~12.31 )
¹ý·ü»ó´ã
µ¿ÀÏ ¾÷Á¾ ±ÝÁö ±Ô¾à ¹®Àǵ帳´Ï´Ù.
¾à±¹°æ¿µ°ú â¾÷
1³â µÚ¿¡ º´¿ø ó¹æÀüÀÌ ¾î´À Á¤µµ µÉ Áö ±Ã±ÝÇÕ´Ï´Ù
¼¼¹«»ó´ã
Áõ¿©¼¼¿¡ °üÇØ ¹®ÀÇ µå¸³´Ï´Ù
¾à»ç½Å¿ë´ëÃâ
È®Àå °ü·Ã ´ëÃâ ¹®ÀÇ µå¸³´Ï´Ù.
¾à»ç´ëÃâ
¾à±¹ÀÌÀü½Ã ´ëÃâ¹®ÀÇÀÔ´Ï´Ù.
¾à±¹ÈÀåÇ°
Æ°»ìÅ©¸² ¹®ÀÇ
¼¼¹«¡¤³ë¹«
¾à±¹ »ó°¡ ¸Å¸Å °ü·Ã¹®ÀÇÀÔ´Ï´Ù.
±³À° °Á ¹× ¾Ë¸² ±¤°í ¾È³» ÆäÀÌÁö
¿¬¼ö, ±³À°, ¼¼¹Ì³ª, Çмú°Á ¹× ±â¾÷±³À°, ¸ðÁý
°øÇ¥, Åä·Ðȸ, ÀǾàÇ° º¯°æ ¾È³» ¹× °¢Á¾ Çà»ç
¾Ë¸² ±¤°í¸¦ Çص帳´Ï´Ù.
(Á¢¼ö ¹®ÀÇ ¹Ù·Î°¡±â)
µ¥Àϸ®ÆÊ ´Üµ¶
Á¦¾à»ç´Â ¾î¶»°Ô ¹ß»ç¸£Åº ±¸»ó±Ý ¼Ò¼Û µÚÁý¾ú³ª
'ÀÚ´©ºñ¾Æ' ³Ñ±ä Çѱ¹MSD »ç¾÷ºÎ Ãà¼Ò¡¦Èñ¸ÁÅðÁ÷ ½Ç½Ã
Á¦¾à, »êÀںΡ¤±âÀçºÎ¿¡ "Åå½Å ±¹°¡Çٽɱâ¼ú ÇØÁ¦¸¦"
´ç´¢º´¾à ÀÚ´©ºñ¾Æ ºÒ¼ø¹° °ËÃ⡦ÀϺΠÁ¦Ç° ȸ¼ö
Àü¹®¾à»ç ÃÖÁ¾¾È 'Áö¿ª»çȸ¾à·á¡¤ÀǾàÁ¤º¸' °á±¹ ºüÁ®
³ì½ÊÀÚ, 1200¾ï Ç×Ç÷¼ÒÆÇÁ¦ 'Çöóºò½º' °°ÀÌ ÆÇ´Ù
'À¯Åë °ø·æ' Áö¿À¿µ ´õ Ä¿Áö³ª...2À§ ¹éÁ¦ ÁöºÐ ¸ÅÀÔ ÃßÁø
´ëÇÐ Çõ½Å½Å¾àÇаú ½Å¼³ ÃßÁø...»ê¾÷¾à»ç ÀÔÁö Èçµé?
³ì½ÊÀÚ, GSK »õ ´ë»óÆ÷Áø ¹é½Å '½Ì±×¸¯½º' °°ÀÌ ÆÇ´Ù
´ë¿õÁ¦¾à SGLT-2 ´ç´¢ ½Å¾à '¿£ºí·Î' ¸íÂû ´Þ¾Ò´Ù
Dailypharm KOREA
Breast cancer Tx Ibrance¡¯s AE rate at 86%...6yr PMS results
Xospata makes progress for reimb...up for DREC review
Scemblix is listed in July
IND of LegoChem Bio's ADC was approved by the FDA
Expansion of indications for Forxiga as a treatment for HFrE
ÆʼîÇθô
ÀǾàÇ°¸ô
Çコ¿ëÇ°¸ô
±âŸ»óÇ°¸ô
Àϼº½Å¾à
¸ÞµðÄ«ÄÚ¸®¾Æ
¿¥¿¡ÇÁ¾¾
À¯´Ï¸Þµå
¶ó¿ÂÆĸ¶
Çdzª¿ÂÁ¤
¸ÞµðÄ«ÄÚ¸®¾Æ
ÃÊÀÓ°è¾ËƼÁö
Àϼº½Å¾à
Ç÷ç¾ÆµåÄõµå
À¯´Ï¸ÞµåÁ¦¾à
¸ÞµðÆʸô
¸ÞµðÄ®Çö´ë
¸¶´õ½ºÁ¦¾à
¸¶´õ½ºÁ¦¾à
ÄÜƼ600
¿¥¿¡ÇÁ¾¾
¾Æ·Î´Ï¾Æ´Ü¹éÁú¹Ù
´õÆÊÀÌÁö¹Ù¿ï
¸¶½ºÅÍ
À¯´Ï¸ÞµåÁ¦¾à
À¯´Ïµ§Å»¿ÃÄɾîÄ¡¾à
ÈÞº£À̽º
KnH¸ÞµðÅØ
°æ¹æ½Å¾à
¸Þµð¶óÀÌÇÁ
ÂøÇѳª¹«ÀÎÅ׸®¾î
³»¼Õ¾ÈÀÇ ¾à±¹
´ÚÅ;ØÆÊ
¾à»ç ½Å¿ë´ëÃâ
¾à»ç¸¦ À§ÇÑ ¾à±¹ Ç÷§Æû
¼±ÅÃÀÇ ÆøÀ̳оîÁø ¾à±¹Ã¼ÀÎ
°æ¹æ½Å¾à
°æ¿Á°í
¾à±¹ÀÎÅ׸®¾î
¾à»ç´Ô ÀÔ¼Ò¹®
¾à±¹»ó´ã¼Ò
¾à»ç´ëÃâ
¼¼¹«»ó´ã
¾à±¹°æ¿µ
¹ý·ü»ó´ã
¾à»ç½Å¿ë´ëÃâ
¼¼¹«¡¤³ë¹«
¾à±¹ÈÀåÇ°
¹ý·ü»ó´ã
µ¿ÀÏ ¾÷Á¾ ±ÝÁö ±Ô¾à ¹®Àǵ帳´Ï´Ù.
- ¹ý¹«¹ýÀÎ ±Ô¿ø -
¾à»ç´ëÃâ
¾à±¹ÀÌÀü½Ã ´ëÃâ¹®ÀÇÀÔ´Ï´Ù.
- ±è¼ºÈñ ´ëÇ¥ -
¾à»ç½Å¿ë´ëÃâ
È®Àå °ü·Ã ´ëÃâ ¹®ÀÇ µå¸³´Ï´Ù.
- ±è´ë°Ç ½ÇÀå -
¾à±¹ÈÀåÇ°
Æ°»ìÅ©¸² ¹®ÀÇ
- ±è¿µ¼± ¾à»ç -
¾à±¹°æ¿µ°ú â¾÷
1³â µÚ¿¡ º´¿ø ó¹æÀüÀÌ ¾î´À Á¤µµ µÉ Áö ±Ã±ÝÇÕ´Ï´Ù
- ±èÇöÀÍ ¾à»ç -
¼¼¹«¡¤³ë¹«
¾à±¹ »ó°¡ ¸Å¸Å °ü·Ã¹®ÀÇÀÔ´Ï´Ù.
- ÀÓÇö¼ö ´ëÇ¥ -
¼¼¹«»ó´ã
Áõ¿©¼¼¿¡ °üÇØ ¹®ÀÇ µå¸³´Ï´Ù
- ±èÇåÈ£ ¼¼¹«»ç -
±âȹ¡¤Å½»ç
±âȹ
ºÐ¼®
ÇöÀå
Çؼ³
DPÃÊ´ë¼®
¹Ì·¡Æ÷·³
Ä«µå´º½º
À¥Å÷º¹¾àÁöµµ
"°íÀÛ ¾à±¹ 12°÷?"...¾à»çȸ ¼ÒºÐ°Ç±â½Ä ¾îµð±îÁö ¿Ô³ª
ºôµù¸¶´Ù ÇÑ °÷¾¿¡¦¾Æ»ê ÅÁÁ¤½Åµµ½Ã ¾à±¹ ºÐ¾ç°¡ 30¾ï
Áö¿ªµ¹º½¹ý, º¹¾àÁöµµ È®´ë¡¦Á¤ºÎ-ÁöÀÚü-¾à»ç Çù·Â ¼÷Á¦
"¹Ì±¹ Ãâ°Ý ÀÌ»ó¹«"¡¦³ì½ÊÀÚ '¾Ë¸®±Û·Î' »ý»ê ±¸½½¶¡
¿ÀÇǴϾð
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
Ưº°±â°í
±âÀÚ¼öø
[µ¥½ºÅ©½Ã¼±] ¸®º£ÀÌÆ®·Î ½×¾Æ ¿Ã¸° ±ÝÀÚž
³ëº´Ã¶ ±âÀÚ
[µ¥Àϸ®ÆÊ=³ëº´Ã¶ ±âÀÚ] À¯µ¶ Á¦¾à¹ÙÀÌ¿À»ê¾÷¿¡ ´ëÇÑ Á¤ºÎÀÇ °µµ ³ôÀº ¸®º£ÀÌÆ® ¼ö»ç ¿øÀÎÀº ¹»±î. ¿ø·ÐÀûÀ¸·Î µûÁö¸é À¯Åë Åõ¸íÈ¿¡ ±âÀÎÇÑ´Ù. ±×·¸Áö¸¸ °¡Àå ±Ù¿øÀû ÀÌÀ¯´Â Àü¹®ÀǾàÇ°ÀÇ ±¹¹Î°Ç°º¸Çè ¾à°¡ ...
[±âÀÚÀÇ ´«] ÀÌ·ÊÀûÀÎ '¿£ÇãÅõ' ±Þ¿©¿Í ½Å¾à ÀÌÁ¤Ç¥
¾îÀ±È£ ±âÀÚ
[±âÀÚÀÇ ´«] ÀϺΠŸÀÌ·¹³î Ç°¸ñ, »ý»êÁß´Ü 2³â° »óºñ¾à ¸ñ·Ï¿¡
ÀÌÇý°æ ±âÀÚ
[±âÀÚÀÇ ´«] µ¿¾Æ½î½Ã¿À¿Í ¿¹Ãø°¡´É¼ºÀÇ Èû
À̼®ÁØ ±âÀÚ
ÆʾÆÄ«µ¥¹Ì
Á¦Ç°°ÁÂ
Çмú°ÁÂ
°æ¿µ°ÁÂ
OTC»ó´ã Àü¹®°¡°úÁ¤
'ȯÀÚ¿¡°Ô ²À ¸Â´Â ¾Æ¸£±â´Ñ ¼±Åùý'
'NSAIDs + Ç÷·ù°³¼±À¸·Î ¹¶Ä£ ÅëÁõ ¿ÏÈ!'
'È°¼ººñŸ¹Î 3Á¾¿¡ ¸é¿ª°È ¹Ì³×¶ö±îÁö MAX'
'¿Ã¹Ù¸¥ »óó¿Í È»ó°ü¸® ¹æ¹ý!'
ÆÊTV
ÆÊÅäÅ©
À̽´¿µ»ó
ºÎÀÛ¿ë ¸®Æ÷Æ®
OTC¼¿¸µÆ÷ÀÎÆ®
½ºÆ¿ÄÆ¿µ»ó
´ÙÁ¦¾à¹° »ç¾÷À¸·Î ó¹æÁ¶Á¤±îÁö¡¦ÀÇ¡¤¾à»ç Çù¾÷ Áß¿ä
ÇؿܾడÀçÆò°¡, ÀïÁ¡°ú Á¦¾à»ê¾÷°è ¹Ý¹ß ÀÌÀ¯´Â?
22´ë ÃѼ± ÀǾà»ç ±â»óµµ¡¦ÀÇ´ëÁ¤¿ø °¥µî Àå±âÈ
"Á¤ºÎ¡¤¾÷°è ±ÔÁ¦ÀÎ½Ä ±«¸®, Çù·Â°ú ¼ÒÅëÀ¸·Î ÃÖ¼ÒÈ"
Á¤Ã¥°ú ¹ý·ü
°Ç°º¸Çè
ÀǾàÇ°
ÀǷᡤ¾à¹«
¹ý·É
Àü°øÀÇ¡æ±³¼ö Àü¼±³ÐÈù ÀÇ·á°è¡¦Ä¡Å²°ÔÀÓ µÈ ÀÇÁ¤°¥µî
ÀÌÁ¤È¯ ±âÀÚ
[µ¥Àϸ®ÆÊ=ÀÌÁ¤È¯ ±âÀÚ] "2000¸í (Áõ¿ø) Á¤¿øÀ» Ç®¾îÁÖ¼Å¾ß ÇÕÀÇ°¡ µÉ °Í" ¹æÀç½Â Àü±¹ÀÇ´ë±³¼öÇùÀÇȸ ºñ´ëÀ§¿øÀå "ÀÇ´ë ±³¼ö »çÁ÷ °áÀÇ´Â ±¹¹Î »ý¸í ÀüÁ¦ÇÑ °Ì¹ÚÀÌÀÚ ¹ýÄ¡ µµÀü" ¹Ú¹Î¼ö º¹ÁöºÎ ...
¸ù°ñ ¿Ü°úÀÇ»ç ½Â±Þ½ÃÇè ¿ä°Ç¿¡ ÁøÈï¿ø ¿¬¼ö ÁöÁ¤
ÀÌÇý°æ ±âÀÚ
±è¼±¹Î Àü ½ÉÆò¿øÀå, Á¶±¹Çõ½Å´ç ºñ·Ê 5¹ø ¹èÁ¤
ÀÌÁ¤È¯ ±âÀÚ
"ÀÇ´ë±³¼ö »çÁ÷ ½Ã ¿øÄ¢ ´ëÀÀ¡¦2õ¸í ±Ô¸ð ³íÀÇ ¿·ÁÀÖ´Ù"
ÀÌÁ¤È¯ ±âÀÚ
¿ø¹®ÀÚ·á
Àüü
|
ÇàÁ¤
|
Á¦¾à
|
º¸µµ
|
¾à»ç
|
ÀÇ·á
|
[ÇàÁ¤]
ÀǾàÇ° Á¤º¸ ÀüÀÚÀû Á¦°ø ´ë»ó ÀǾàÇ°
[Á¦¾à]
(¡¯24.3.1 Àû¿ë) 948°³ Ç°¸ñ(º¸Çè¾à°¡
[ÇàÁ¤]
2022³â ÁöÃ⺸°í¼ °á°ú
[ÇàÁ¤]
·¹ºñƼ¶ó¼¼Å½, Ŭ·Î¹ÙÀá ¼ººÐ ÀǾàÇ° ¸ñ·Ï
[ÇàÁ¤]
±¹°¡ÇʼöÀǾàÇ° ¸ñ·Ï
Á¦¾à¡¤¹ÙÀÌ¿À
±â¾÷
R&D¿Í ¾à¹°
Çã°¡¿Í ƯÇã
À¯Åë°ú ¸¶ÄÉÆÃ
Á¦¾à´Üü
»óÀåÁ¦¾à Àý¹Ý ¿µ¾÷ÀÍ¡é...´ëÇü¡¤Áß¼Ò ½ÇÀû ¾ç±ØÈ ½ÉÈ
±èÁø±¸ ±âÀÚ
[µ¥Àϸ®ÆÊ=±èÁø±¸ ±âÀÚ] Áö³ÇØ ÁÖ¿ä »óÀå Á¦¾à¹ÙÀÌ¿À±â¾÷ 50°÷ Áß 27°÷(54.0%)ÀÇ ¼öÀͼºÀÌ ¾ÇÈÇß´Ù. ƯÈ÷ Áß¼ÒÇüÁ¦¾à»çµéÀÇ ¼öÀͼº ¾ÇÈ°¡ µÎµå·¯Á³´Ù. ¿¬¸ÅÃâ 5000¾ï¿ø ¹Ì¸¸ Á¦¾à»ç 32°÷ °¡¿îµ¥ 22°÷(68.8%)...
´ë¿õÁ¦¾à "¿£ºí·Î, ½ÅÀåÁúȯ ´ç´¢º´¼ °æÀï¾àº¸´Ù È¿°ú"
¼ÕÇü¹Î ±âÀÚ
¼¿Æ®¸®¿Â, ¹Ì±¹¼ 'ÁüÆæÆ®¶ó' ¹ß¸Å...ù ½Å¾à Ãâ°Ý
õ½ÂÇö ±âÀÚ
¼¿·¦¸Þµå, ¹Ì±¹¾Ï¿¬±¸ÇÐȸ¼ »õ·Î¿î CAR-T Àü·« °ø°³
³ëº´Ã¶ ±âÀÚ
[±âÀÚ Àü¹® ÄÚ³Ê]
'»ýÁ¸±â°£ ¿¬Àå'¡¦±Û·Î¹úÁ¦¾à, ¿ä·Î»óÇÇ¾Ï Á¤º¹ µµ
[Á¦¾à¡¤¹ÙÀÌ¿À ±â¾÷ºÐ¼®]
½Å»ç¾÷ ÁøÃ⡤CMO È®´ë...´ë¿õ¹ÙÀÌ¿À, ±ÔÁ¦°È Á¤
º´¿ø¡¤¾à±¹
ÀǾà´Üü
»ê¾÷°ú °æ¿µ
ºÎµ¿»ê¡¤¼¼¹«
»ç°Ç°ú ¼Ò¼Û
¾àÇС¤Çмú
ÀÇ»ç Áý´ÜÇൿ¿¡ '´ç´¢ ¼Ò¸ð¼º Àç·á' ¾à±¹ ¸®ÇÊ Çã¿ë
°Çý°æ ±âÀÚ
[µ¥Àϸ®ÆÊ=°Çý°æ ±âÀÚ] ÀÇ»ç Áý´ÜÇൿ¿¡ Á¤ºÎ°¡ ´ç´¢ ¼Ò¸ð¼º Àç·á ¸®ÇÊÀ» Çã¿ëÇß´Ù. ó¹æÀü ¹ß±Þ ¾øÀÌ Á÷Àü ó¹æÀü°ú µ¿Àϻ󺴡¤µ¿ÀÏó¹æ Á¦Ç°¡¤Ã³¹æ±â°£¿¡ ÇÑÇØ ±Þ¿©±â°£ ¿¬Àå ¹× Á¦Ç° ±¸ÀÔÀ» Çã¿ëÇÑ °ÍÀÌ´Ù. ...
ÀÓÇöÅà ¼Òû°úÀÇ»çȸÀå, º¹ÁöºÎ À塤Â÷°ü °ø¼öó °í¹ß
°½Å±¹ ±âÀÚ
ÆÄÁÖ¿¡ 2È£ ´Þºû¾î¸°À̺´¿ø ÁöÁ¤...Çù·Â¾à±¹µµ ¿î¿µ
°½Å±¹ ±âÀÚ
°Ç¾à "Ç°Àý¾à, ±¹°¡Ã¥ÀÓÁ¦°¡ ´ä"¡¦Á¤´ç¿¡ ¿ä±¸¾È Àü´Þ
°Çý°æ ±âÀÚ
Áö¿ªº° ´Ùºóµµ ÀϹݾà ÆǸŰ¡°Ý Á¤º¸(2024³â 03¿ù)
´ë±¸-°æºÏÁö¿ª ¾à±¹ 37°÷
Á¦Ç°¸í
ÃÖ°í
ÃÖÀú
°¡°ÝÂ÷
Æò±Õ
µÑÄÚ¶ô½º¿¡½ºÁ¤(20Á¤)
6,500
6,500
0
6,500
ÈѽºÅ»Ç÷¯½ºÁ¤(10Á¤)
3,500
2,500
1,000
3,144
»ßÄÞ¾¾Á¤(100Á¤)
24,000
22,000
2,000
22,800
¾Æ·Î³ª¹Î°ñµåÁ¤(100Á¤)
30,000
27,000
3,000
28,586
¸¶µ¥Ä«¼ÖÄɾ°í(10g)
8,000
5,500
2,500
6,773
ÈĽõò¿¬°í(5g)
5,500
4,000
1,500
5,104
°ÖÆ÷½º¿¥ÇöŹ¾×(4Æ÷)
5,000
3,500
1,500
4,350
Àλ絹Ç÷¯½ºÁ¤(100Á¤)
37,000
30,000
7,000
33,889
ÀÌ°¡Åº¿¡ÇÁĸ½¶(100Á¤)
35,000
29,000
6,000
31,083
Áö¸£ÅØÁ¤(10Á¤)
6,000
4,500
1,500
5,238
°Ôº¸¸°Á¤(10Á¤)
4,000
3,300
700
3,699
ºñÄڱ׸°¿¡½º(20Á¤)
5,000
4,000
1,000
4,597
ÆæÀßÅ¥Á¤(10Á¤)
3,500
2,500
1,000
3,073
±î½ºÈ°¸í¼öÅ¥¾×(1º´)
1,200
1,000
200
1,199
Ç®Äɾî(3.3ml)
27,000
25,000
2,000
26,143
¿À¶ó¸Þµð¿¬°í(10g)
7,000
6,000
1,000
6,463
ÄÉÅäÅéÇöó½ºÅ¸(34¸Å)
13,000
11,000
2,000
12,009
³ë½ºÄ«³ª°Ö(20g)
22,000
18,000
4,000
20,462
º£³ªÄ¡¿À¿¡ÇÁ¾×(1º´)
1,000
1,000
0
1,000
¸Ó½Ã·ÐÁ¤(21Á¤)
10,000
7,000
3,000
9,121
´ÚÅͺ£¾ÆÁ¦Á¤(10Á¤)
3,500
2,500
1,000
3,126
ÆÇÄÝ¿¡½º³»º¹¾×(1¹Ú½º)
3,000
2,800
200
2,984
Å׶óÇ÷糪ÀÌƮŸÀÓ(6Æ÷)
8,000
7,000
1,000
7,952
ºñ¸ß½º¸ÞŸÁ¤(120Á¤)
60,000
55,000
5,000
57,842
Ź¼¾¿¬Áúĸ½¶(10ĸ½¶)
3,000
2,000
1,000
2,992
ÀÓÆÑŸ¹ÎÇÁ¸®¹Ì¾ö(120Á¤)
60,000
50,000
10,000
55,000
º¹ÇÕ¿ì·ç»ç(60ĸ½¶)
30,000
25,000
5,000
27,844
ŸÀÌ·¹³îER(6Á¤)
3,000
2,500
500
2,912
ºñÆÇÅÙ¿¬°í(30g)
12,000
9,800
2,200
11,515
ÅÙÅÙÃòÁ¤(120Á¤)
25,000
22,000
3,000
24,429
¾Æ·º½º´ëÇü(6¸Å)
4,000
3,000
1,000
3,498
Æǽõôĸ½¶(270ĸ½¶)
120,000
105,000
15,000
116,250
º¥Æ÷º§Á¤B(120Á¤)
70,000
60,000
10,000
64,111
±×³¯¿£(10Á¤)
3,000
2,500
500
2,810
ÀÌÁö¿£6À̺ê(10Á¤)
3,500
2,100
1,400
3,027
±¤µ¿ °æ¿Á°í(60Æ÷)
220,000
200,000
20,000
212,000
¾ÆÀÌÅåÁ¡¾È¾×
12,000
10,000
2,000
10,967
Àüüº¸±â